Alzheimer’s Disease

Alzheimer’s Disease

Overview

Alzheimer’s disease (AD) is a progressive neurodegenerative condition responsible for 50%–60% of dementia cases.1 It is marked by cognitive decline and behavioral changes. Early pathological indicators, such as the accumulation of β-Amyloid plaques and Tau neurofibrillary tangles, can be identified decades before symptoms emerge.2 Advanced biomarkers now enable earlier and more precise detection of these changes, improving the diagnosis and management of Alzheimer’s disease.3

Cerebrospinal Fluid (CSF) biomarker testing provides a reliable alternative to amyloid PET imaging, with approximately 90% concordance between the two methods.4 This testing enhances diagnostic accuracy and empowers clinicians to make more informed decisions.5 Additionally, Blood-based testing is gaining momentum: 87% of physicians expect it to become the standard of care.6

Did You Know?

Physicians believe nearly 1 in 5 seniors (18%), on average, may be living with undiagnosed AD6

of adults want to detect AD risk as part of prevention care6

of patients living with dementia are not formally diagnosed3

seniors are living with AD in 2025. This number is projected to double by 20507

Alzheimer’s Disease Testing Portfolio

Alzheimer’s Disease Evaluation Profile, CSF Biomarkers
Measures ß-Amyloid 1-42 (Aβ42), Phospho Tau 181 (pTau181), and Total Tau (tTau)

Blood-Based Biomarkers*
Measures Aβ42, APOE4, GFAP, NfL, pTau181, Phospho Tau 217 (pTau217), and tTau

Cognitive Screening & Early Detection
Screening identifies individuals at risk, while biomarker testing helps differentiate AD from other causes of cognitive decline1 and supports timely intervention

Collection Methods
CSF & Blood-based biomarker

Methodology
Electrochemiluminescence Immunoassay (ECLIA)

Integrative Ordering
Results directly within EMR. Results typically available within 48-72 hours

Impact of Early Intervention

  • Improved Care Coordination
  • Proactive Health Management
  • Legal & Financial Planning
  • Early Access to Amyloid-Targeting Therapies
  • Positive Mindset: A patient’s beliefs about their own cognitive decline might accelerate or delay its effects8
  • Cost-Savings: An early diagnosis at the mild cognitive impairment (MCI) stage could save ~$7 trillion in medical & long-term costs in the U.S. alone7

*These biomarkers (Phospho Tau 217 (pTau217), Aβ42, APOE4, GFAP, NfL, and tTau) were developed and their performance characteristics determined by TrilliumBiO. They have not been cleared or approved by the U.S. Food and Drug Administration.

References: 1. World Health Organization. Dementia. March 15, 2023. Accessed March 17, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia 2. Jack CR Jr, et al. Lancet Neurol. 2010;9(1):119-128. doi:10.1016/S1474-4422(09)70299-6 3. Jack CR Jr, et al. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018 4. Rabinovici GD, et al. JAMA. 2019;321(13):1286-1294. doi:10.1001/jama.2019.2000 5. Cognat E, et al. BMJ Open. 2019;9(5):e026380. doi:10.1136/bmjopen-2018-026380 6. Quest Diagnostics. The Coming Alzheimer’s Disease Healthcare Revolution: US Physician and Adult Perspectives on the Future of Diagnostics and Treatment. May 2022. Accessed July 1, 2024. 7. Alzheimer’s Association. 2025 Alzheimer’s disease facts and figures | https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf. Accessed October 20, 2025. 8. Baylor College of Medicine. The ethics of telling Alzheimer’s diagnosis and the power of communication. April 2025. Accessed October 23, 3025.

Please contact TrilliumBiO to establish an account and receive your collection supplies before completing the test order below.